On May 26, 2020 MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that it will host an investor and analyst video webcast event on Tuesday, June 2nd, 2020 at 8:00 AM ET following the ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program (Press release, MEI Pharma, MAY 26, 2020, View Source [SID1234558453]). The event will include a review of the ME-401 program, the recent data presented at ASCO (Free ASCO Whitepaper)20, and commentary from key opinion leader Matthew J. Matasar, M.D., a board-certified medical oncologist/hematologist and Attending Physician, Lymphoma Service, and Medical Director, Memorial Sloan Kettering – Bergen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Video Webcast Information

You can access the live video webcast under the investor relations section of MEI’s website on the "Events and Presentation" page at: www.meipharma.com. A replay of the video webcast will be archived for at least 30 days after the conclusion of the live event.

On May 26, 2020 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported it will host a conference call and audio webcast on Friday, May 29, 2020 from 5:00 p.m. to 6:00 p.m. ET / 2:00 p.m. to 3:00 p.m. PT (Press release, CytomX Therapeutics, MAY 26, 2020, http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-host-conference-call-and-webcast-review-asco [SID1234558452]). CytomX management will review oral and poster presentations from the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in CytomX Therapeutics’ ASCO (Free ASCO Whitepaper) 2020 Conference Call, please access the call by dialing 1-877-809-6037 (United States) or 1-615-247-0221 (International) referencing Conference ID 4267278. The listen-only audio and slide webcast of the conference call can be accessed under "Events & Presentations" of the Investor Relations section of the Company’s website at View Source Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be located under the Investor Relations section of CytomX’s website approximately two hours after the conclusion of the live call and will be available for 30 days following the call.

On May 26, 2020 Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 8:30 a.m. Eastern Time (Press release, Selecta Biosciences, MAY 26, 2020, View Source [SID1234558451]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and a copy of the presentation will be available on the Investors & Media section of the Selecta website at www.selectabio.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 90 days.

On May 26, 2020 Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") reported it has received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for STI-6129, a CD38-targeting antibody drug conjugate (ADC) (Press release, Sorrento Therapeutics, MAY 26, 2020, View Source [SID1234558450]). STI-6129 utilizes several technology platforms that are under development by Sorrento Therapeutics, including a CD38 specific antibody identified from its fully human G-MAB antibody library, its proprietary drug payload Duostatin 5 and its site-specific C-LOCK conjugation technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"That the FDA cleared our STI-6129 IND application to proceed to human trials is another important milestone for Sorrento," stated Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. "Together with our CD38 CAR-T program, this has the potential to provide additional therapeutic options for patients in need. We are looking forward to further evaluating the safety and efficacy of STI-6129 in clinical trials."

Sorrento intends to initiate a phase I multicenter, open-label, dose-escalation clinical trial in patients with advanced relapsed and/or refractory systemic amyloid light chain (AL) amyloidosis with a primary objective to identify a phase 2 dose for STI-6129 based on its safety, preliminary efficacy and pharmacokinetic profile.

"This is Sorrento’s first ADC utilizing our site-specific C-LOCK conjugation technology that is advancing into clinical evaluation," said Dr. Hui Li, head of Sorrento’s ADC business unit, Levena Biopharma. "STI-6129 demonstrated an improved therapeutic index in animal models, as compared to traditional non-selective conjugates, and we look forward to potentially expanding its utilization into additional ADC programs."

On May 26, 2020 Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, reported that Victoria Richon, Chief Executive Officer, will provide a corporate overview and an update on the company’s lead clinical program, PARP7 inhibitor RBN-2397, at the Jefferies 2020 Virtual Healthcare Conference (Press release, Ribon Therapeutics, MAY 26, 2020, View Source [SID1234558448]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference – June 2-4, 2020
Corporate Presentation
Presenter: Victoria Richon, PhD – President and CEO
Date: June 2, 2020
Time: 3:00 p.m. EDT